Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire•04/11/2026•07:05 ET
1
Key Highlights
- ➤Unicycive CEO Shalabh Gupta will present at Guggenheim healthcare conference November 10
- ➤Oxylanthanum carbonate targets hyperphosphatemia in dialysis patients with chronic kidney disease
- ➤UNI-494 received FDA orphan drug designation for preventing delayed graft function
- ➤UNI-494 completed a Phase 1 dose-ranging safety study in healthy volunteers
Expert Statements
Shalabh Gupta, Chief Executive Officer of Unicycive Therapeutics
“will present at the Guggenheim 3rd Annual Healthcare Innovation Conference”
MOUNTAIN VIEW, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 2:30 p.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.
Get started
Create a free account to read the full story.